Epiomic Epidemiology Series: Crohn’s Disease Forecast in 12 Major Markets 2017-2027

Epiomic Epidemiology Series: Crohn’s Disease Forecast in 12 Major Markets 2017-2027

  • January 2017 •
  • 68 pages •
  • Report ID: 5178663 •
  • Format: PDF
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Crohn’s Disease in 12 Major Markets

Crohn’s disease, also known as regional enteritis, is a type of chronic inflammatory bowel disease. While it may affect any part of the gastrointestinal tract, it most commonly affects the ileus and colon. It is thought to be an auto-immune disease, although this theory has been challenged in recent years.

This report provides the current prevalent population for Crohn’s disease across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Brazil, Japan, China, India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Crohn’s have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Crohn’s disease include:
• Gastritis and duodenitis
• Anaemia
• Other autoimmune diseases
• Deep vein thrombosis
• Skin problems; ulcers, blisters, swelling
• Inflammation of joints

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
• Able to quantify patient populations in global Crohn’s disease’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Crohn’s disease and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Crohn’s disease’s prevalent population.
• Identify sub-populations within Crohn’s disease which require treatment.
• Gain an understanding of the specific markets that have the largest number of Crohn’s disease patients.

We are very sorry, but an error occurred.
Please contact [email protected] if the problem remains.